Exploration of suitable pharmacodynamic parameters for acarbose bioequivalence evaluation: A series of clinical trials with branded acarbose

AIMS: To determine deficiencies in the Food and Drug Administration (FDA)'s guidance for assessing acarbose bioequivalence (BE) and to explore optimal pharmacodynamic (PD) metrics for better evaluation of acarbose BE. METHODS: Three clinical trials with branded acarbose were conducted in health...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Jie, Liu, Wen‐yu, Yu, Jing‐jing, Yang, Jin‐bo, Li, Min, Zou, Chan, Guo, Cheng‐xian, Yang, Xiao‐yan, Yang, Shuang, Xie, Jin‐lian, Huang, Zhi‐jun, Chen, Hui, Pei, Qi, Yang, Guo‐ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7576622/
https://www.ncbi.nlm.nih.gov/pubmed/32333407
http://dx.doi.org/10.1111/bcp.14324

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7576622/
https://www.ncbi.nlm.nih.gov/pubmed/32333407
http://dx.doi.org/10.1111/bcp.14324

Ejemplares similares